Ibogaine reduces amphetamine-induced locomotor stimulation in C57BL/6By mice, but stimulates locomotor activity in rats.
H Sershen, L G Harsing, A Hashim, A Lajtha
Life sciences January 1, 1992 DOI: 10.1016/0024-3205(92)90498-e via PubMed
Summary
AI-generated from the abstractIbogaine hydrochloride reduced the locomotor stimulation caused by low-to-moderate doses of d-amphetamine in male mice, an effect that lasted two days, but did not block the effect of a high dose. A lower dose of ibogaine was ineffective. Ibogaine decreased striatal dopamine levels by 30%, while d-amphetamine increased them by 26%. In rats, ibogaine pretreatment paradoxically increased d-amphetamine-induced locomotion, indicating species specificity. The findings suggest ibogaine can modulate dopamine-related behavioral effects in a dose- and species-dependent manner.
Study at a glance
| Characteristics | Experimental study Peer reviewed |
|---|---|
| Population | Male C57BL/6By mice and female Sprague-Dawley rats |
| Interventions | Ibogaine hydrochloride d-amphetamine sulfate |
| Dose | 40 mg/kg ibogaine; 1, 5, or 10 mg/kg d-amphetamine; 20 mg/kg ibogaine |
| Citations | 33 |
| Key finding | Ibogaine pretreatment reduces d-amphetamine-induced locomotor stimulation in mice but increases it in rats, and these effects are associated with changes in striatal dopamine levels. |
Abstract
The effect of ibogaine hydrochloride on locomotor stimulation induced by d-amphetamine sulfate was tested in male C57BL/6By mice and in female Sprague-Dawley rats. In mice, locomotor stimulation induced by d-amphetamine at 1 or 5 mg/kg s.c. was reduced by prior administration of one or two injections of ibogaine (40 mg/kg), given 2 or 18 hours earlier. This reduction in locomotor activity persisted for two days. Locomotor stimulation induced by a higher dose (10 mg/kg) of d-amphetamine was not reduced by such prior administration of ibogaine. A lower dose of ibogaine (20 mg/kg) did not reduce the subsequent locomotor activity induced by d-amphetamine. Ibogaine decreased striatal dopamine levels, while d-amphetamine increased them. Ibogaine treatment (2 x 40 mg/kg, 18 hours apart) induced a decrease by 30% in the level of striatal dopamine and its metabolites measured in tissue extracts 3 hours after the second ibogaine injection. One hour after d-amphetamine (5 mg/kg) administration, the level of striatal dopamine increased by 26%. Although the level of striatal dopamine was initially lower in the ibogaine-pretreated mice, d-amphetamine (5 mg/kg) administration induced an increase in striatal dopamine and its metabolites. The effect of ibogaine seems to be species specific, since in rats pretreated with ibogaine 18 hours before d-amphetamine, locomotor stimulation induced by d-amphetamine was further increased. In addition, the in vitro electrical-evoked release of [3H]dopamine from striatal tissue was either unchanged or inhibited in the presence of d-amphetamine, and after ibogaine pretreatment in vivo, the release of tritium in the presence of d-amphetamine was inhibited or stimulated in mice and rats, respectively.